Attenuation of hind-limb ischemia in mice with endothelial-like cells derived from different sources of human stem cells.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Stem Cell Transplantation*; Endothelial Cells/*transplantation ; Induced Pluripotent Stem Cells/*cytology ; Ischemia/*pathology ; Ischemia/*therapy; Aged ; Angiogenic Proteins/metabolism ; Animals ; Bone Marrow Cells/cytology ; Cell Differentiation ; Cell Hypoxia ; Culture Media, Conditioned/pharmacology ; Cytokines/metabolism ; Endothelial Cells/cytology ; Hindlimb/pathology ; Humans ; Male ; Mice ; Middle Aged ; Neovascularization, Physiologic ; Perfusion ; Time Factors

Functional endothelial-like cells (EC) have been successfully derived from different cell sources and potentially used for treatment of cardiovascular diseases; however, their relative therapeutic efficacy remains unclear. We differentiated functional EC from human bone marrow mononuclear cells (BM-EC), human embryonic stem cells (hESC-EC) and human induced pluripotent stem cells (hiPSC-EC), and compared their in-vitro tube formation, migration and cytokine expression profiles, and in-vivo capacity to attenuate hind-limb ischemia in mice. Successful differentiation of BM-EC was only achieved in 1/6 patient with severe coronary artery disease. Nevertheless, BM-EC, hESC-EC and hiPSC-EC exhibited typical cobblestone morphology, had the ability of uptaking DiI-labeled acetylated low-density-lipoprotein, and binding of Ulex europaeus lectin. In-vitro functional assay demonstrated that hiPSC-EC and hESC-EC had similar capacity for tube formation and migration as human umbilical cord endothelial cells (HUVEC) and BM-EC (P>0.05). While increased expression of major angiogenic factors including epidermal growth factor, hepatocyte growth factor, vascular endothelial growth factor, placental growth factor and stromal derived factor-1 were observed in all EC cultures during hypoxia compared with normoxia (P<0.05), the magnitudes of cytokine up-regulation upon hypoxic were more dramatic in hiPSC-EC and hESC-EC (P<0.05). Compared with medium, transplanting BM-EC (n = 6), HUVEC (n = 6), hESC-EC (n = 8) or hiPSC-EC (n = 8) significantly attenuated severe hind-limb ischemia in mice via enhancement of neovascularization. In conclusion, functional EC can be generated from hECS and hiPSC with similar therapeutic efficacy for attenuation of severe hind-limb ischemia. Differentiation of functional BM-EC was more difficult to achieve in patients with cardiovascular diseases, and hESC-EC or iPSC-EC are readily available as "off-the-shelf" format for the treatment of tissue ischemia.

Eur J Heart Fail. 2007 Aug;9(8):747-53. (PMID: 17481945)
Eur Heart J. 2007 Dec;28(24):2998-3005. (PMID: 17984132)
Diabetes Metab Res Rev. 2011 Feb;27(2):185-94. (PMID: 21294240)
Eur Heart J. 2008 Aug;29(15):1807-18. (PMID: 18523058)
Circulation. 1999 Aug 3;100(5):547-52. (PMID: 10430770)
Cell Reprogram. 2010 Dec;12(6):665-78. (PMID: 20964482)
Int J Cardiol. 2013 Jul 1;166(3):709-15. (PMID: 22188988)
Lancet. 2012 Mar 10;379(9819):870-871. (PMID: 22336188)
Cell Reprogram. 2010 Dec;12(6):641-53. (PMID: 20858051)
Circulation. 2007 Nov 20;116(21):2409-19. (PMID: 17984381)
Stem Cells Dev. 2011 Oct;20(10):1701-10. (PMID: 21235328)
Circ Res. 2001 Jul 6;89(1):E1-7. (PMID: 11440984)
Coron Artery Dis. 2008 Aug;19(5):327-35. (PMID: 18607170)
Tissue Eng Part A. 2012 Feb;18(3-4):310-9. (PMID: 21902465)
Nat Protoc. 2009;4(12):1737-46. (PMID: 19893509)
Stem Cell Rev Rep. 2010 Jun;6(2):297-306. (PMID: 20180049)
Cell Stem Cell. 2007 Jun 7;1(1):39-49. (PMID: 18371333)
J Am Coll Cardiol. 2010 Aug 10;56(7):593-607. (PMID: 20688215)
Circ Res. 2008 Jun 6;102(11):1319-30. (PMID: 18535269)
Cell Stem Cell. 2010 Nov 5;7(5):618-30. (PMID: 20888316)
J Am Soc Nephrol. 2011 Jul;22(7):1221-8. (PMID: 21636641)
Cell. 2007 Nov 30;131(5):861-72. (PMID: 18035408)
J Cell Mol Med. 2011 Aug;15(8):1726-36. (PMID: 21029373)
Lancet. 2003 Jan 4;361(9351):47-9. (PMID: 12517468)
Circulation. 2005 Sep 13;112(11):1618-27. (PMID: 16145003)
Science. 2007 Dec 21;318(5858):1917-20. (PMID: 18029452)

0 (Angiogenic Proteins)
0 (Culture Media, Conditioned)
0 (Cytokines)

Date Created: 20130309 Date Completed: 20131203 Latest Revision: 20231106

20240829

PMC3589485

10.1371/journal.pone.0057876

23472116